 MONROVIA, Calif.--BUSINESS WIRE--Xencor, Inc. NASDAQ:XNCR, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced updated data from its ongoing Phase 1 dose-escalation study of vibecotamab XmAb14045, a CD123 x CD3 bispecific antibody, in patients with relapsed or refractory acute myeloid leukemia AML. The data were presented in an oral session at the 62nd American Society of Hematology 